Glioblastoma is the most frequent and most aggressive brain tumour in adults.
cancer stem-like properties was suppressed, such as SOX2 protein expression. 10 Hao et al demonstrated that resveratrol combination with TMZ had significant efficacy on glioblastoma progression.
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Some studies also explored the effects of TMZ on glioblastoma cells activities. For example, miR-146b-5p enhanced cell duplication and impeded cell apoptosis through mediating TMZ resistance in glioblastoma cells. 12 The mechanism of TMZ interacting with other molecules in glioma cells is crucial to the therapies of glioma.
Polo-like kinase 1 protein (PLK1) was reported to highly express in various tumours. By overriding the G2-M DNA damage and spindle checkpoints, overexpression of PLK1 can promote chromosome aneuploidy and instability. 13 Chemical inhibitors or knockdown of PLK1 decreased medulloblastoma cells growth. 13 Robin et al illuminated that PLK1 was promoted in CD133-positive cells and combined inhibition of PLK1 and BRAF resulted in significantly greater pro-apoptotica and anti-proliferative effects than those achieved by monotherapy. 5 Koncar et al researched the interaction of TMZ and PLK1 in glioma, and reported that combination treatment of TMZ and a PLK1 inhibitor BI2536 caused significant cancer shrinkage and tumour regression in in vivo experiments, while TMZ or BI2536 alone had little effect on tumour growth. 14 The influence of TMZ and PLK1 on glioma cellular activities needs to be further studied.
In this study, we evaluated the effects of PLK1 on glioblastoma and the synergistic inhibition effect of PLK1 inhibitor combined with TMZ on human brain glioma stem cells in vitro and vivo. Our study suggested that PLK1 inhibitors may be a novel therapies target for glioma treatment.
| MATERIALS AND METHODS

| U87 and U251 CD133-positive cells isolation and culture
The human glioblastoma cell line U87 and U251 was obtained commercially from ATCC and were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% bovine serum and 100 μg/mL streptomycin. For the isolation, U87 and U251 cells were suspended at FcR reagents were added for blocking. Microbeads cultured with CD133 antibody (ab19892, Abcam, Cambridge, MA) were then added, and the mixture was cultured at 37°C for 1 hour. Cells collected was recognized as CD133-fractions while cells obtained after removing the magnetic holder was diagnosed as CD133 + cells, also as glioma stem cells. Glioma stem cells were cultured in a serum-free DMEM-F12 medium (Invitrogen) supplemented with 10 ng/mL basic fibroblast growth factor (bFGF, Invitrogen), 20 mg/mL epidermal growth factor (EGF, Invitrogen) and 2% B27 (Invitrogen) under 5% CO 2 at 37°C. 
| Cell transfection
| Flow cytometry assay
Monolayer cultured human glioma CD133-U87 and CD133-U251 cells and stem cells were fixed in the ice-cold ethanol (70%) at −20°C overnight. Then the cells were first incubated in the RNAse and stained with propidium iodide. Cell cycle analysis was carried out on a FACS Calibur flow cytometer (Thermo Fisher scientific, Inc., Beijing, China), and the obtained data were analysed using Cell Quest software (BD Biosciences, San Jose, CA, USA). GAPDH was considered as the internal reference.
| Soft agar colony formation assay
The bottom layer of soft agar (0.9%) was prepared in a six-well plate, 
| GSC sphere-forming assays
GSC spheres were enzymatically dissociated to single cells and replated in 96-well plates at optimal density (500-1000 cells) in nonadherent conditions. Cells were cultured in serum-free DMEM-F12 medium (Invitrogen) supplemented with 10 ng/mL bFGF, 20 ng/mL EGF and 2% B27. Half of the medium was renewed every other day, and after 6 days, the cells were fixed with 4% formalin. The cells were photographed and spheres larger than 50 μm were counted.
| Tumour xenografts in mice
Forty-two male athymic BALB/c nude mice (4-week-old) were 2. Thirty days after the injection, the mice were killed and the tumours were dissected for analyses.
| Haematoxylin and eosin (HE) staining
The tumour tissues obtained from mice were fixed with 10%
formaldehyde, embedded in paraffin, cut into 4 μm sections and 
| Statistical analysis
Each assay was conducted in triplicate. Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, La Jolla, CA). Student's t test was applied to compare the differences between two groups, while the differences between multi-samples were analysed by analysis of variance (ANOVA). P value of <0.05
was considered statistically significant. 
| PLK1 was involved in TMZ tolerance
We 
| PLK1 inhibitor displayed synergistic activity with TMZ to inhibit CD133 + U87 stem cells growth in vivo
We also examined whether the combination of PLK1 inhibitor and | 5309
whether glioma stem cells are equipped with stronger capability for drug resistance than glioma cells. The results showed that TMZ effectively attenuated the duplication and cell cycle of glioma cells and stem cells in a dose-dependent manner and had a greater effect on U87 cells and U251 cells, which revealed the presence of different resistant mechanism in glioma cells and glioma stem cells. Consistently, the suppressive effect of TMZ on TJ905 glioma cells was more significant than its effect on TJ905 stem cells. 18 And Beier et al also discovered that glioblastoma stem cell had stronger resistance to TMZ compared with glioblastoma cells. 4 Relevant studies have revealed the PLK1 was involved in the mechanism of cancer growth. For instance, PLK1 was elevated in glioblastoma multiforme cells and its inhibition suppressed cell growth and induced cell death. 19 In medulloblastoma, down-regulation of PLK1 impaired tumour sphere formation of medulloblastoma cells and induced cell apoptosis. 13 Additionally, Koncar et al demonstrated that PLK1 inhibition enhanced TMZ efficacy in IDH1 mutant gliomas.
14 Additional modalities of TMZ-resistant such as PLK1 expression further complicate the mechanism of glioma drug resistance. Hence, we employed experiments to examine the interaction of PLK1 and TMZ in TMZ-resistant glioma cells, and found that PLK1 expression was impeded with the increase in TMZ concentration.
Furthermore, PLK1 inhibitor or knockdown of PLK1 facilitated the inhibitory effect of TMZ on cell viability and cell cycle.
Although we have elucidated the links between PLK1 expression and TMZ efficacy on U87 and U251 stem cells, the current study also has some unavoidable limitations. For example, other molecules involved in drug-resistant glioma stem cells are worthy to be studied.
In summary, our study proposed the synergistic inhibition effect of PLK1 inhibitor with TMZ on glioblastoma stem-like cells and suggested the critical role of PLK1 in glioma stem cells progression, providing new treatment strategies for gliomas.
